Orca-Q is under clinical development by Orca Biosystems and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Orca-Q’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orca-Q is under development for the treatment of acute myeloid, lymphoid or mixed phenotype leukemia, myelodysplastic syndromes, myelofibrosis, and chronic myeloid leukemia (CML) who were matched to haploidentical allogeneic donors, defined as matched across at least 4/8 but fewer than 7/8 human leukocyte antigen (HLA) loci, hematopoietic stem cell transplantation. The drug candidate comprises of allogenic, fully controlled cell product candidate that contains a next-generation formulation of T cells. It is developed based on OrcaSort technology.
Orca Biosystems overview
Orca Biosystems (Orca Bio) is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. The company is headquartered in Menlo Park, California, the US.
For a complete picture of Orca-Q’s drug-specific PTSR and LoA scores, buy the report here.